Biltmore Family Office’s Cadrenal Therapeutics CVKD Stock Holding History

Biltmore Family Office’s Portfolio CVKD Stock Details CVKD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-733	Closed	-$5.17K	–	273
2024 Q2	$5.17K	Hold	733	–	–	﹤0.01%	236
2024 Q1	$6.71K	Hold	733	–	–	﹤0.01%	224
2023 Q4	$8.14K	Hold	733	–	–	﹤0.01%	221
2023 Q3	$7.48K	Buy	+733	New	+$10.4K	﹤0.01%	229

Other funds holding CVKD

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Biltmore Family Office's CVKD Position: Q3 2024 in Review

Biltmore Family Office sold out of Cadrenal Therapeutics (CVKD) in Q3 2024, closing a stake of 733 shares — an estimated $5.17K sold.

Biltmore Family Office first reported a position in CVKD in Q3 2023 and held it in 4 quarters. The position peaked at $8.14K in Q4 2023. 2 funds tracked by Wall St. Rank hold CVKD as of Q3 2024.

Biltmore Family Office reported no remaining Cadrenal Therapeutics position as of Q3 2024 after selling out during the quarter.
Biltmore Family Office sold 733 Cadrenal Therapeutics shares in Q3 2024, an estimated $5.17K.
Biltmore Family Office first reported a position in Cadrenal Therapeutics in Q3 2023 and held it in 4 quarters.
Biltmore Family Office's Cadrenal Therapeutics position peaked at $8.14K in Q4 2023.
2 funds tracked by Wall St. Rank held Cadrenal Therapeutics as of Q3 2024.

Based on Biltmore Family Office's 13F filing for Q3 2024, filed 12 Nov 2024.